Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Chr. Hansen Holding A/S
  6. News
  7. Summary
    CHR   DK0060227585


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chr Hansen A/S : . Hansen completes acquisition of Jennewein

10/12/2020 | 02:10am EDT
Chr. Hansen completes acquisition of Jennewein

Chr. Hansen Holding A/S ('Chr. Hansen') today announced that it has successfully completed the acquisition of Jennewein Biotechnologie GmbH ('Jennewein') following the satisfaction of all closing conditions.

With the acquisition which is fully in line with its 2025 Strategy, Chr. Hansen further extends its microbial and fermentation technology platforms while entering the high-growth Human Milk Oligosaccharides ('HMO') market which is estimated to have a size of more than EUR 400 million in 2025 and more than EUR 1 billion long-term.

Jennewein is recognized as a global leader in the HMO market with a strong product portfolio, global customer base and highly cost competitive, IP-protected production process. The company with headquarters in Bonn, Germany, has around 100 employees and will operate as a separate, full value chain and Chr. Hansen's fifth lighthouse under Health & Nutrition.

Chr. Hansen plans to invest more than EUR 200 million until 2025, mainly in a new state-of-the-art manufacturing facility in Kalundborg, Denmark, and expects to unlock significant scalability benefits in fermentation and efficiencies during the strategy period.

In 2020/21, Jennewein is expected to generate sales of around EUR 50 million, but with a net EBIT loss. The HMO business is expected to be EBIT margin dilutive until scale in the business is realized. However, beyond 2024/25 the EBIT margin potential is expected to be similar to the existing Chr. Hansen business. Chr. Hansen's long-term financial ambition remains unchanged.

Jennewein has been acquired for a total consideration of EUR 310 million on a debt-free basis.

The acquisition was announced on September 22, 2020.

For further information please contact:

Martin Riise, Head of Investor Relations, Tel: +45 5339 2250

Annika Stern, Investor Relations Officer, Tel: +45 2399 2382

Camilla Lercke, Head of Media Relations, Tel:+45 5339 2384

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world's most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose -To grow a better world. Naturally. - is at the heart of everything we do.


Chr. Hansen Holding A/S published this content on 12 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2020 06:09:02 UTC

ę Publicnow 2020
All news about CHR. HANSEN HOLDING A/S
05/31CHR HANSEN A/Sá : . Hansen JV With Lonza Obtains Manufacturing License In Denmar..
05/31CHR HANSEN A/Sá : Bacthera receives manufacturing licenses in Switzerland and De..
05/31CHR HANSEN A/Sá : . Hansen launches global science-based online platform on prob..
05/18CHR. HANSEN HOLDING A/S : Infrequent or one-off capital gain payment
05/17CHR HANSEN A/Sá : Extraordinary dividend
05/12CHR HANSEN A/Sá : . Hansen and Nestlé settle court case about Human Milk Oligosa..
05/11CHR HANSEN A/Sá : Sustainability roadshow presentation (May 2021)
05/11CHR HANSEN A/Sá : . Hansen launches VEGA™ Culture Kit specifically develop..
04/28CHR HANSEN A/Sá : . Hansen launches the next generation of FreshQ« food cultures..
04/28CHR HANSEN A/Sá : . Hansen launches the next generation of FreshQ« food cultures..
More news
Sales 2021 1 075 M 1 275 M 1 275 M
Net income 2021 868 M 1 030 M 1 030 M
Net Debt 2021 812 M 963 M 963 M
P/E ratio 2021 11,7x
Yield 2021 2,34%
Capitalization 10 165 M 12 061 M 12 055 M
EV / Sales 2021 10,2x
EV / Sales 2022 9,48x
Nbr of Employees 3 286
Free-Float 77,9%
Duration : Period :
Chr. Hansen Holding A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHR. HANSEN HOLDING A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Average target price 75,74 €
Last Close Price 77,16 €
Spread / Highest target 13,2%
Spread / Average Target -1,84%
Spread / Lowest Target -14,6%
EPS Revisions
Managers and Directors
Mauricio Graber President & Chief Executive Officer
Lise Skaarup Mortensen Chief Financial Officer & Executive Vice President
Dominique Reiniche Chairman
Thomas Schńfer Chief Scientific Officer & Executive VP
Winnie Hojvang BŘgel VP-Compliance & Corporate Communications
Sector and Competitors